NICE recommends rimegepant for treating acute migraine in adults

The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the oral treatment rimegepant as a cost effective option for acute treatment of migraine in adults.1Draft guidance published on 14 September recommends rimegepant (also called Vydura and made by Pfizer) for adults who have tried at least two triptans—a group of medicines used for treating migraine or headache—but found that they did not work well enough.NICE said that around 13 000 people could benefit from this treatment on the NHS. It has previously recommended treatments including rimegepant for preventing migraine in adults.2The draft guidance also recommends rimegepant for adults who are unable to take triptans or found that they were not tolerated, where non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol were also tried but did not work well enough. It cites clinical trial evidence showing that rimegepant is more likely to reduce pain at two hours than…
Read Original Article: NICE recommends rimegepant for treating acute migraine in adults »